← Back to Treatments
🏅 FDA Orphan Designation

Haegarda

C1 esterase inhibitor subcutaneous (human)

Manufacturer: CSL Behring LLC

Indicated for:
Hereditary angioedema

FDA-Approved Indications (1)

For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients

Population: adolescents and adults

Indications & Usage

For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. ||| HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.